Satellos Bioscience (MSLE) Net Income (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Net Income came in at -$9.8 million in Q1 2026, down 259.06% year-on-year from $6.1 million in Q1 2025, and down 259.06% on a QoQ basis from $6.1 million in Q1 2025.
Satellos Bioscience (MSLE) Net Income (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Net Income data on file, last reported at -$9.8 million in Q1 2026.
- On a quarterly basis, Net Income fell 259.06% year-over-year to -$9.8 million in Q1 2026; TTM through Mar 2026 was -$3.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$25.0 million, down 23.54% from the prior year.
- Net Income for Q1 2026 stood at -$9.8 million, down from $6.1 million in the prior quarter.
- Over the last five years, Net Income for MSLE reached as high as $6.1 million in Q1 2025 and fell as low as -$9.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Satellos Bioscience | 182.60 Mn | 182.60 Mn | - | -9.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.77 Mn |
| Mar 31, 2025 | 6.14 Mn |